We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Proposes Eight-Month Review of Priority Generics, Plans for Wave of Biosimilars
FDA Proposes Eight-Month Review of Priority Generics, Plans for Wave of Biosimilars
The FDA officially unveiled its recommendations for the second generation of user fee agreements covering generics and biosimilars, with commitments to eight-month reviews of priority generics.
